This morning Senseonics, an implantable glucose sensor company, announced that data from its Eversense continuous glucose monitor will be integrated into the Glooko diabetes management platform.
This means that users of the Eversense CGM and app will now be able to sync it with the Glooko online platform and app, and be able to see historical blood glucose-related data as well as get updates with real-time glucose readings.
The new integration also means that clinicians will be able to see a patient’s CGM data via the Glooko Population Tracker and other data from Glooko.
Why it matters
The companies are pitching this integration as a way to help people get a fuller picture of their health.
“Glooko has a large database of millions of users who are now able to see a clearer picture of their glucose profiles by integrating Eversense CGM data,” Tim Goodnow, president and CEO of Senseonics, said in a statement. “With personalized medicine at the forefront of health care, data integration between Eversense CGM and Glooko helps provide customized data for users, as well as healthcare providers. We believe this information can empower our community to help manage their diabetes with new insights and actions and, ultimately, improve lives.”
What's the trend
In July Senseonics got FDA clearance to market Eversense in the US. It was a long time in the making, as the company was waiting on this clearance since November 2016.
In the interim the company launched the CGM globally. In fact, in 2018 the company unveiled a monitoring app for its users in Europe, the Middle East and Africa, where its CGM system is distributed by Roche.
On the record
"We are excited to launch support for the breakthrough Eversense CGM on the Glooko platform,” Russ Johannesson, CEO of Glooko, said in a statement. “Eversense is an innovative solution for making glucose data more accessible, and we feel users will get tremendous value out of seeing this data correlated with food, activity and medication information they log in Glooko to help them make treatment decisions."